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Abstract The reg gene, previously described in islets of 90% 
pancreatectomized and nicotinamide-treated rats, has been 
shown to be expressed in many pharmacological or surgical 
animal models of beta cell regeneration. We have studied the 
non-obese diabetic (NOD) mouse, which represents a good model 
of spontaneous autoimmune diabetes in which regenerative 
processes have recently been demonstrated. Two reg genes have 
been described in the mouse genome, both recognized by the 
human reg cDNA. In a previous work, using the human probe, we 
have demonstrated a strong correlation between pancreatic reg 
gene expression and the likelihood of developing diabetes. In the 
present study, we have examined the respective levels of both 
mouse reg I and reg II mRNA in the NOD mouse pancreas using 
their specific cDNA probes. We found that reg II expression was 
specifically prevalent compared to reg I, irrespective of sex or 
state of the disease. Reg II mRNA was particularly increased in 
overtly diabetic female mice and in cyclophosphamide-treated 
male mice. These data underline the need to study separately the 
reg genes using specific probes and show that both reg genes are 
subjected to various regulations, strongly suggesting that their 
physiological functions may be different. 
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1. Introduction 
The pathogenesis of type I or insulin-dependent diabetes 
mellitus is characterized by immune-mediated destruction of 
beta cells in the islets of Langerhans of the pancreas. Some 
regenerating islets have been found in the pancreas of recently 
diagnosed diabetic patients [1]. Thus the balance between the 
speed of destruction and regeneration may determine the out-
come of the process, i.e. overt disease or subclinical islet in-
flammation [2]. The non-obese diabetic (NOD) mouse pro-
vides a good experimental model of human type I diabetes 
[3] and O'Reilly et al. have recently provided evidence of islet 
neogenesis from duct epithelium in diabetic NOD mice [4]. 
Therefore the NOD model appears to be a valuable model 
for the study of the balance between destruction and regener-
ation of pancreatic islets. One hypothesis is that the reg gene, 
previously described in regenerating islets of partially pancrea-
tectomized rats [5], could play a central role in the induction 
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of a replicative process. In a previous study, using a human 
reg cDNA probe, we showed for the first time in the NOD 
model a strong correlation between reg gene expression and 
diabetic risk [6]. Indeed we found pancreatic overexpression of 
the reg gene in NOD female mice which are known to be 
prone to develop diabetes early in life whereas NOD males, 
which are relatively protected, have a low reg mRNA level 
similar to that found in a control mouse strain. The specificity 
of the phenomenon was reinforced by the reg overexpression 
observed in NOD male mice after cyclophosphamide treat-
ment, a potent inducer of diabetes, whereas this drug had 
no effect in control male mice. Since two reg genes have 
been characterized in the mouse genome [7], these first data 
could not reflect the relative expression of both reg genes. In 
the present study, using reg I and reg II specific cDNA 
probes, we quantified reg I and reg II mRNA levels at various 
stages of diabetogenesis. We demonstrate here that the expres-
sion of the reg II gene was in all cases higher than that of reg I 
in the NOD mouse pancreas, for female, male and overtly 
diabetic female mice. 
2. Materials and methods 
2.1. Animals and treatment 
NOD mice bred from a parental stock provided by Dr. С Boitard 
(Department of Immunology, INSERIVI U25, Necker Hospital, Paris, 
France) were fed ad libitum. In our colony the cumulative prevalence 
of diabetes at day 210 was 43% in females and < 1% in male mice. 
Glycosuria was detected using labsticks (Ketodiastix, Ames-Bayer Di-
agnostica, France). 
In order to select situations with various degrees of activity of 
diabetogenic process we studied: (1) 22 non-diabetic NOD male 
mice (age range: 57-268 months); (2) 16 non-diabetic NOD female 
mice (age range: 53-319 months); (3) 13 overtly diabetic NOD female 
mice (age range: 80-248 months). The animals were killed less than 
5 days after the diagnosis of diabetes; (4) six cyclophosphamide-in-
jected NOD male mice (age 110 days). Cyclophosphamide (Endoxan, 
Lucien Laboratory, France) in saline was injected subcutaneously at a 
dose of 300 mg/kg body weight 100 days after birth. Since in our 
colony the percentage of overt diabetes in NOD male mice was 16% 
after one injection and 83% after two injections of cyclophosphamide, 
the animals were killed 10 days after the first injection whilst in a 
'prediabetic' period. 
In addition nine female and 11 male 100 day old mice (IOPS-OF1) 
supplied by Iffa Credo (France) were studied as controls. Six IOPS-
OF1 male mice were injected with cyclophosphamide with the same 
protocol as described for NOD male mice. 
2.2. Probes 
The reg I and reg II probes were kindly provided by H. Okamoto; 
they were full-length cDNA, 750 bp for reg I and 700 bp for reg II, 
subcloned into pBluescript vector at the Xhol site in the polycloning 
site. Before hybridization, both were digested with Xhol enzyme and 
purified on agarose before labeling. The 28S cDNA probe (ATCC) 
was used as a control for RNA concentrations. 
The insulin cDNA probe was synthesized by RT-PCR with 1 μg of 
total mouse pancreatic RNA according to the instructions provided 
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with the Gene Amp RT-PCR kit (Perkin Elmer Cetus). The primers 
used in the PCR reactions were deduced from the nucleotide sequen-
ces of mouse insulin II [8]. They were as follows: sense primer 5'-CC-
CACCCAGGCTTTTGTCAA-3' (nucleotides 1193-1213) and anti-
sense 5'-CTCCAGCTGGTAGAGGGAGC-3' (nucleotides 1919-
1938). 
Thirty-five cycles of amplification were performed using the follow-
ing conditions: (1) denaturation for 1 min at 95°C, (2) primer anneal-
ing for 1 min at 67°C, and (3) extension for 1 min at 72°C. After 
amplification, the RT-PCR products were analyzed by electrophoresis 
on a 10% acrylamide gel. The correct size of the fragment (258 bp) 
was checked by ethidium bromide visualization. The fragment 
was then subjected to electrophoresis on a 1.5% agarose/TAE 
(50XTAE:2 M Tris-acetate, 0.05 M EDTA) gel and cut up. The 
DNA was separated from agarose by centrifugation using Spin X 
column (Costar) and the correct sequence was assessed by the dideoxy 
chain termination method using the Sequenase sequencing kit (U.S. 
Biochemical Corp., Ohio). 
2.3. RNA extraction and Northern blot analysis 
The isolation of total pancreatic RNA was performed using the 
RNAzol method (Bioprobe Systems, France) according to the method 
described by Chomczynski et al. [9] which is particularly suitable for 
small samples (weight s 200 mg). The RNA concentration was moni-
tored by absorbance at 260 nm (1 OD = 40 μg/ml). The integrity of 
total RNA was confirmed by 1% agarose/formaldehyde electrophore-
sis. 
Northern blot analysis of electrophoretically separated pancreatic 
total RNA was performed to verify the hybridization specificity of 
each probe. In brief, total RNA was transferred to a nitrocellulose 
membrane (Schleicher and Schüll, Keene, NH) and hybridized accord-
ing to the procedure described by Maniatis et al. [10] with the cDNA 
probes labelled with [a-32P]dCTP (3000 Ci/mmol, Amersham, France) 
using a random primer kit (Appligène, France) for reg I, reg II and 
insulin or a nick translation kit (Gibco BRL, Life Technologies, 
France) for the 28S cDNA probe. The specific activities of the probes 
were routinely 109 and 108 cpm^tg for random priming and nick 
translation labeling, respectively. Results were visualized by autora-
diography. 
2.4. Specificity of reg I and reg II cDNA probes 
The reg I and reg II cDNA were subcloned into pBluescript, which 
carries bacteriophage T3 and T7 promoters, and were then tran-
scribed, after linearization, into the sense orientation respectively by 
T7 or T3 RNA polymerase. After precipitation, the synthetic RNAs 
were subjected to electrophoresis on an agarose/formaldehyde gel and 
transferred on nitrocellulose [10]. Filters were hybridized with labelled 
reg I or reg II cDNA probes. Results were visualized by autoradiog-
raphy. 
2.5. Quantitative analysis of mRNA by dot blot hybridization 
Sequential dilutions of total RNA were spotted on nitrocellulose 
membranes using a manifold apparatus (Minifold I, Schleicher and 
Schüll). For hybridization with reg I, reg II and insulin probes, the 
dilutions were from 5 μg to 0.156 μg. For hybridization with the 28S 
cDNA probe, we decreased the amount of total RNA 100-fold, and 
therefore, the sequential dilutions were from 50 ng to 1.56 ng. After 
spotting, the filters were baked for 2 h at 80°C before hybridization. 
In brief, filters were prehybridized for 4 h at 42°C in a solution con-
taining 50% formamide, 5XSSPE (20XSSPE: 3 M NaCl, 0.02 M 
EDTA and 0.2 M NaH2P04-2H20), 5 X Denhardt's reagent and 400 
μ$/ηι1 of salmon sperm DNA. Hybridization was performed for 36 h 
at 42°C in the above solution containing 0.1% SDS, using IX Den-
hardt's reagent instead of 5X and containing the cDNA probe la-
belled with [a-32P]dCTP. After hybridization, filters were washed four 
times for 5 min in 2XSSC, 0.1% SDS at room temperature and twice 
for 15 min in 0.1 X SSC, 0.1% SDS at 52°C. Results were visualized by 
autoradiography. Filter-bound radioactivity was determined by scan-
ning autoradiograms at 490 nm using an automatic microplate reader 
(MR 5000 Dynatech). The mRNA concentrations were calculated 
from the linear regression of dot scans. For each sample, the densito-
metrically scanned readings for reg were corrected to the 28S signal to 
eliminate possible differences in total RNA loading. Results were cal-
culated as the ratio reg I/28S, reg II/28S or insulin/28S and are ex-
pressed in arbitrary units (A.U.). 
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2.6. Statistical analysis 
Results were expressed as means ± S.E.M. The significance of 
mRNA expressions between the mouse groups was determined using 
Student's unpaired i-test. 
3. Results 
3.1. Specificity of reg I and reg II probes 
In view of the homology which exists between reg I and reg 
II sequences it was important to ensure the specificity of the 
reg I and reg II c D N A probes. We confirmed that cross-hy-
bridization between reg I and reg II did not occur under the 
hybridization conditions of high stringency that we used. We 
prepared synthetic R N A using recombinant pBluescript for 
reg I or reg II c D N A . The in vitro transcription reactions 
were performed using T7 or T3 R N A polymerases. These 
R N A were hybridized with reg I and reg II c D N A probes. 
As shown in Fig. 1, reg I c D N A did not hybridize with reg II 
R N A and reg II c D N A did not hybridize with reg I R N A . 
3.2. Qualitative analysis of mRNA by Northern blot 
The results of Northern blot analyses are shown in Fig. 2. 
Each m R N A was identified as a single band and the transcript 
sizes were, as expected, 0.9 kbp for reg I and reg II. 
3.3. Specific over expression of the reg II gene in the NOD 
pancreas 
3.3.1. Non-diabetic animals. The patterns of pancreatic ex-
pression of the reg I and reg II genes during aging of non-
diabetic N O D female and male mice are presented in Fig. 3. 
Despite the large interindividual variation of values we ob-
served a specific and significant increase of reg II m R N A 
compared to reg I (P < 0.05 for female and P < 0.005 for 
male mice). As shown in Fig. 4A, the comparison of the ex-
pression of the two reg genes before 130 days of age shows a 
prevalent reg II m R N A level in both female (4.97 ± 1.34 A.U. 
vs. 2.39 ± 0 . 4 A.U., P < 0 . 0 5 ) and male (3 .4110 .79 A.U. vs. 
1.55 ± 0.27 A.U., P< 0.05) N O D mice. In contrast, in control 
OF1 mice, studied at the same age (Fig. 4B), there was a 
significant fourfold lower reg II m R N A level (0.09 ± 0.02 
A.U. for females and 0.16 ±0 .05 A.U. for males) compared 
^^^—^^^— probes 
reg I reg II 
28 S -+-
18 S -»-
I II I II 
Fig. 1. Specificity of reg I and reg II probes. Synthetic RNAs from 
reg I and reg II cDNA, subcloned into pBluescript, were obtained 
after linearization using T7 or T3 RNA polymerase respectively. 
After electrophoresis and transfer onto nitrocellulose, the synthetic 
RNAs were hybridized either with a reg I cDNA-labeled probe or 
with a reg II cDNA-labeled probe. 
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Fig. 4. Comparative levels of pancreatic reg I (D) and reg II (■) 
mRNA in NOD and control mice below 130 days of age. A: Diabe-
tes-prone female and male NOD mice. B: Control female and OF1 
mice. Results are expressed in A.U. as means ± S.E.M. Statistical 
significance indicated by *P<0.05, ***p< 0.001. 
Fig. 2. Northern blot of NOD mouse pancreatic mRNA. Total 
RNA isolated from mouse pancreas was denatured and subjected to 
electrophoresis on a 1% agarose gel. After transfer onto a nitrocel-
lulose membrane, it was hybridized with the mouse reg I cDNA-la-
beled probe or the mouse reg II cDNA-labeled probe. Positions of 
28S and 18S rRNAs are indicated. 
to reg I (0.3710.04 A.U., P< 0.001 for females and 
0.67 ±0.06 A.U., P< 0.001 for males). In addition, as previ-
ously shown with the human reg cDNA probe, the mouse reg 
I and reg II mRNA levels were significantly higher in NOD 
mice than in control OF1 mice. 
3.3.2. Diabetic female and cyclophosphamide-injected male 
mice. As shown in Fig. 5, the higher expression of reg II 
described in the NOD strain was even more evident in dia-
betic females with a ratio reg II/reg I of 4.07 ± 0.49 which was 
approximately twofold higher than the ration of the non-dia-
betic NOD female mice (1.77 ±0.37). In contrast, the level of 
reg I mRNA expression was equivalent in diabetic and non-
diabetic females (respectively 2.07 ±0.43 A.U. and 2.16 ±0.29 
A.U.). It is interesting to note that in cyclophosphamide-in-
jected male mice there was a much larger overexpression of 
the reg II gene (21.6 ±6.86 A.U.) compared to normal male 
mice (P<0.001); however, the reg I gene expression level 
(1.38 ±0.47 A.U.) was similar in these treated animals com-
pared with non-treated NOD males with a low risk of devel-
oping diabetes (0.91 ±0.19 A.U.). 
3.4. Insulin gene expression in NOD and OFI pancreas 
In addition to reg gene expression, we studied the expres-
sion of the insulin gene in NOD mice which is critical in 
diabetogenesis where the insulin-producing beta cells are irre-
versibly destroyed. The results are presented in Fig. 6A. The 
diabetic NOD females did not express insulin mRNA with the 
exception of one, 150 days old, which exhibited an extremely 
Fig. 3. Pancreatic reg I (o) and reg II (·) mRNA levels and varia-
tion with age in NOD female (A) and male (B) mice. Quantification 
was performed by blot as described in Section 2. Results are ex-
pressed in arbitrary units (A.U.). 
Fig. 5. Levels of pancreatic reg I (D) and reg II (■) mRNA in male 
(M), female (F), diabetic female (DF) and cyclophosphamide-treated 
male (CyM) NOD mice. Results are expressed in A.U. as means 
±S.E.M. *P<0.05, **P<0.01. 
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Fig. 6. Levels of insulin mRNA. A: Diabetes-prone male (M), fe-
male (F), diabetic female (DF) and cyclophosphamide-treated male 
(CyM) NOD mice. B: Control male (M) and female (F) OF1 mice. 
Results are expressed as means ± S.E.M. **P<0.01. 
low level of insulin transcription (0.023 A.U.). No difference 
was found between non-diabetic NOD females and males for 
which the values were respectively 0.2710.03 A.U. and 
0.21 ±0.04 A.U. An increase in insulin expression 
(0.47 ±0.12 A.U.) was found in cyclophosphamide-treated 
NOD male mice and the level was significantly higher than 
that measured in non-treated NOD male (P<0.01) and in 
non-diabetic NOD female mice (P<0.01). 
In OF1 mice (Fig. 6B), both female and male, the insulin 
mRNA levels were approximately twofold higher than in 
NOD mice and were respectively 0.52 ±0.15 and 0.58 ±0.05 
A.U. Finally, no increase in insulin expression was found in 
the OF1 cyclophosphamide-injected male mice (data not 
shown). In all cases no correlation was found between the 
expression of both reg genes and of the insulin gene. 
4. Discussion 
Using specific mouse reg I and reg II cDNA probes and 
after excluding any cross-reactivity of the probes, we demon-
strate that, as observed with the human reg cDNA probe [6], 
there is a strong correlation between pancreatic reg gene ex-
pression and the diabetic risk. Moreover, we show that, de-
spite the high variation in values, the expression of the reg II 
gene is in most cases higher than that of reg I in the NOD 
mouse pancreas. This phenomenon is specific to the diabeto-
genic strain since the relative expression of each reg gene is 
reversed in the diabetes-resistant strain OF1 where we found a 
ratio reg II/reg I of 0.24 in both male and female mice. This 
ratio was nearly identical to that found by Unno et al. (0.23) 
in the pancreas of C57BL/6J mice who were also diabetes-
resistant [7]. In the NOD strain, the higher level of reg II 
mRNA is even more significant in overtly diabetic female 
mice compared to non-diabetic female mice. So in the NOD 
mouse, as shown in Fig. 5, there is a progressive increase in 
reg II expression which parallels the activity of diabetogenic 
processes. Indeed the reg II mRNA level was at its lowest in 
the resistant male, increasing in the non-diabetic female with a 
high risk of developing diabetes, increasing again in overtly 
diabetic female and finally was at its highest in the cyclophos-
phamide-injected male. In contrast, even if reg I gene expres-
sion is higher in the NOD pancreas compared to controls, it 
does not parallel the level of diabetogenicity. The small sig-
nificant increase of reg I expression observed in the groups 
with the highest reg II expression could be explained either by 
a lower sensitivity to common stimulation or by the action of 
different stimuli. These results allow us to demonstrate that 
the reg gene overexpression accompanying the diabetic risk 
that we previously observed [6] was due to the specific over-
expression of reg II. It is interesting that different behavior of 
the two mouse reg genes was recently reported in normal mice 
by Perfetti et al. [11] who demonstrated a decline in reg I but 
not in reg II mRNA levels during aging in normal mice. All 
these data underline the need to study the two reg genes 
separately using specific probes and show that both reg genes 
are subject to various regulations, strongly suggesting that 
their physiological functions may be different. 
The meaning of reg II overexpression in NOD mice paral-
leling the degree of activity of diabetogenic processes remains 
unclear. It is tempting to consider that it is a defense mecha-
nism against the immune-induced beta cell loss as reg has 
been shown to be in vitro as well as in vivo a beta cell-specific 
growth factor [12-14]. If this hypothesis is true, however, such 
a defense mechanism is largely overwhelmed in the NOD 
mouse as proven by the very high reg II expression found 
in overtly diabetic female and especially in cyclophospha-
mide-treated male mice. The possibility of a correlation be-
tween the diabetogenesis, a progressive increase in reg II ex-
pression and attempts at pancreatic regeneration may be 
tentatively evoked. It has been shown that some cytokines 
can upregulate the expression of reg genes [15] and many 
arguments suggest that the diabetogenicity of immune proc-
esses in the NOD mouse is related to a higher expression of 
IFNy due to THl-type infiltrating T lymphocytes [16]. The 
existence of a balance between islet destruction and regener-
ation and the possible central role of IFNy in these processes 
are both supported by the work of Gu et al. who showed that 
the expression of IFNy in the pancreatic beta cells of trans-
genic mice induced beta cell destruction associated with sig-
nificant mitotic activity of these pancreatic cells, this latter 
process consisting essentially of duct cell proliferation and 
islet neogenesis [17]. More recently O'Reilly et al. examined 
for the first time the pancreatic ductal epithelium of the dia-
betic NOD mouse for evidence of islet regeneration [4]. They 
demonstrated that adult NOD mice have the capacity for duct 
cell proliferation and formation of ductal alpha cells and con-
cluded that neogenesis appears to have been initiated in adult 
NOD mice as a result of the autoimmune process that selec-
tively destroys pancreatic beta cells. No insulin-producing 
cells were observed in the duct epithelium of those animals 
and the authors suggest that this could be due to the absence 
of specific differentiating factors or autoimmune attacks. 
It was therefore interesting to look for a correlation be-
tween reg I and reg II expression and the activity and/or 
mass of the endocrine part of the pancreas. Insulin secretion 
capacity is a critical point in the NOD pancreas where the 
insulin-producing beta cells are irreversibly destroyed by in-
sulitis and cytotoxicity. It is admitted that pancreatic insulin 
content decreased regularly from approximately 6 weeks of 
age in NOD mice [18]. No study existed concerning the tran-
scription rate of insulin genes. So we investigated the insulin 
mRNA level in NOD mice, male and female, in order to study 
the beta cells' capacity of transcription. In both sexes we 
found similar insulin mRNA levels that were approximately 
twofold lower than those found in the control OF1 strain. In 
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diabetic females (12 out of 13) no expression of the insulin 
gene was detected. The individual levels did not show any 
evident decrease in insulin gene expression with age in males 
or in non-diabetic females. We assumed that, despite insulitis, 
some female mice were able to resist diabetes for a long period 
and continued to express insulin genes at a relatively high 
rate. It is noteworthy that cyclophosphamide-injected animals 
exhibited higher insulin expression. This finding can be related 
to the hyperactivity of beta cells in the preclinical phases of 
the disease as suggested by others who described an increased 
fasting proinsulin level which preceded abnormalities of insu-
lin secretion in twins of I D D M patients [19]. 
The observation of high expression of the reg II gene in 
N O D diabetic animals where no insulin m R N A was detect-
able and where regenerating endocrine cells appear to be ex-
clusively composed of progenitor and glucagon-secreting cells 
led us to hypothesize that the overexpression of reg genes does 
not depend upon the presence of beta cells but may be asso-
ciated with a regenerative process. 
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